Hopec Pharma Israeli Company

Hopec Pharma is transforming Non-Muscle Invasive Bladder Cancer (NMIBC) treatment with UPEC-FimON, an innovative immunotherapy. This genetically modified Uropathogenic E. coli triggers targeted immune responses, offering higher efficacy, fewer side effects, and a scalable alternative to Bacillus Calmette-Guérin (BCG). Designed with cost-effective production, UPEC-FimON ensures that advanced cancer care remains accessible to patients worldwide, addressing the challenges of BCG shortages.